Tysabri Archives - The MS Wire

News, info and tips for living with multiple sclerosis

Will Tyruko save MS patients money? Maybe.

Posted on September 5, 2023September 4, 2023

The late August approval of Tyruko (natalizumab-sztn) by the U.S. Food and Drug Administration is big news in the multiple sclerosis world. Tyruko is a biosimilar for Tysabri (natalizumab), and it’s the first biosimilar to gain FDA approval as an MS disease-modifying therapy (DMT). “Tyruko has the potential to extend the reach of natalizumab treatment for [MS] patients, increase healthcare savings and fuel innovation through competition in the market,” Keren…Continue Reading

Are You Willing to Accept More Risk Than Your Neuro?

Posted on January 6, 2020January 5, 2020

As more high-efficacy disease-modifying therapies (DMTs) are being made available, people with multiple sclerosis have to decide how much risk they’re willing to accept in exchange for the treatment’s potential benefits. It’s a tough decision, not made any easier if a patient’s neurologist is unwilling to accept much risk. According to researchers at the University Medical Center Hamburg-Eppendorf in Germany, when it comes to one highly effective DMT, patients are…Continue Reading

"People newly diagnosed with MS will truly benefit from this book, while those of us who’ve lived with MS for a while will wish we’d had it ourselves!…Neurologists should consider keeping a copy of this book in their waiting room because their patients are going to need it." - Tamara K. Sellman, reviewing for Multiple Sclerosis.net.

The Multiple Sclerosis Toolbox is designed for MS "newbies" but it's great info for everyone. I combine more than 40 years of living with MS with some easy to understand info about diagnosis, treatments, visiting the neuro, relationships, mobility aids, travel and more…a lot of what you get in this blog. A paperback and an e-book are available on Amazon.